FDA Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection
TAIPEI, Nov. 21, 2023. Senhwa Biosciences, Inc., a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that U.S. Food and Drug Administration has approved its Phase...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cancer & Oncology | Clinical Trials | Food and Drug Administration (FDA) | Infectious Diseases | Pharmaceuticals | Pneumonia | Rare Diseases | Study